Jiao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiao Wu has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Zhi-Nan Chen
Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi’an, China
9 shared publications Fei Huo
Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi’an, China
8 shared publicationsYifei Qin
Institutes of Biomedicine and Department of Cell Biology, Jinan University, Guangzhou 510632, China
8 shared publicationsZhuan Feng
Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi’an, China
7 shared publicationsPeng Lin
Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, 710032, China
5 shared publicationsQian He
Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Clinical Immunology of Xijing Hospital, Fourth Military Medical University, Xi’an, China
4 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-19
NLRX1 is a critical neutrophil checkpoint modulating ferroptosis and suppressing NETosis to attenuate joint damage in arthritis
Neutrophil extracellular traps (NETs) are key drivers of inflammation and tissue damage in rheumatoid arthritis (RA), yet the mechanisms that restrain NETs overproduction remain unclear. Here, we identify the mitochondrial NOD-like receptor NLRX1 as a critical checkpoint limiting NETs production. The expression of NLRX1 is dysregulated in RA patients. NLRX1 deficiency leads to a profound expansion of the neutrophil population, and neutrophil-specific NLRX1 deficiency results in broad production of cytokines, chemokines, autoantibodies and complement accompanied by markedly accelerated arthritis, exaggerated NETs formation, and enhanced joint damage. Single-cell RNA sequencing reveals that NLRX1 restrains a Padi4 -high neutrophil population that is central to NETosis. Mechanistically, NLRX1 deficiency promotes sustained TRAF6-NF-κB signaling and activates the NRF2-mediated oxidative defense pathway, which confers ferroptosis resistance to extend neutrophil lifespan and provides a prolonged temporal window for continuous NETs formation. NLRX1-knockdown cells exhibit increased NETs release, with a more ordered periodic distribution of myeloperoxidase (MPO) along the citrullinated histone H3 (CitH3)-decorated DNA backbone forming the typical ‘beads-on-a-string’ pattern, suggesting enhanced structural organization of NETs. NETs, known to directly degrade bone matrix through proteolytic enzymes, also promote TNFα production, with the cytokine enriched on NETs structures. TNFα in turn stimulates synovial macrophages to express the pro-osteoclastic factor RANKL, thereby fueling bone destruction. Pharmacological activation of the NLRX1 checkpoint attenuates osteoclast differentiation and joint damage. Collectively, these findings unveil the new role of NLRX1 in regulating neutrophil ferroptosis and NETs production and its potential as a therapeutic target for mitigating cartilage and bone damage in RA.
- 23 September 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-19
Open AccessNLRX1 is a critical neutrophil checkpoint modulating ferroptosis and suppressing NETosis to attenuate joint damage in arthritis
Neutrophil extracellular traps (NETs) are key drivers of inflammation and tissue damage in rheumatoid arthritis (RA), yet the mechanisms that restrain NETs overproduction remain unclear. Here, we identify the mitochondrial NOD-like receptor NLRX1 as a critical checkpoint limiting NETs production. The expression of NLRX1 is dysregulated in RA patients. NLRX1 deficiency leads to a profound expansion of the neutrophil population, and neutrophil-specific NLRX1 deficiency results in broad production of cytokines, chemokines, autoantibodies and complement accompanied by markedly accelerated arthritis, exaggerated NETs formation, and enhanced joint damage. Single-cell RNA sequencing reveals that NLRX1 restrains a Padi4 -high neutrophil population that is central to NETosis. Mechanistically, NLRX1 deficiency promotes sustained TRAF6-NF-κB signaling and activates the NRF2-mediated oxidative defense pathway, which confers ferroptosis resistance to extend neutrophil lifespan and provides a prolonged temporal window for continuous NETs formation. NLRX1-knockdown cells exhibit increased NETs release, with a more ordered periodic distribution of myeloperoxidase (MPO) along the citrullinated histone H3 (CitH3)-decorated DNA backbone forming the typical ‘beads-on-a-string’ pattern, suggesting enhanced structural organization of NETs. NETs, known to directly degrade bone matrix through proteolytic enzymes, also promote TNFα production, with the cytokine enriched on NETs structures. TNFα in turn stimulates synovial macrophages to express the pro-osteoclastic factor RANKL, thereby fueling bone destruction. Pharmacological activation of the NLRX1 checkpoint attenuates osteoclast differentiation and joint damage. Collectively, these findings unveil the new role of NLRX1 in regulating neutrophil ferroptosis and NETs production and its potential as a therapeutic target for mitigating cartilage and bone damage in RA.
- Open Access
- 19 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1768013
Ferroptosis as a therapeutic nexus: traditional Chinese medicine interventions in rheumatoid arthritis
Ferroptosis is an iron-dependent, lipid peroxidation-driven form of programmed cell death that plays an important role in neurodegenerative, neoplastic, and autoimmune diseases. Recent studies in Rheumatoid arthritis (RA) have shown that iron metabolism disorders caused by iron overload and impaired transferrin function lead to the production of reactive oxygen species; ferroptosis-associated pathways, such as dysregulation of the System Xc - /GPX4 axis dysregulation, NCOA4-mediated ferritin autophagy, endoplasmic reticulum stress and ferroptosis pathway crosstalk; as well as ferroptosis plays a regulatory role in a variety of immune cells, such as T-cells, B-cells, macrophages, etc., which collectively constitute a complex disease regulatory network in RA. Studies have shown that traditional Chinese medicine (TCM) and TCM therapeutics can alleviate RA-related symptoms and improve the disease progression and prognosis of RA by regulating iron metabolism, activating the Nrf2/HO-1 antioxidant pathway, and removing abnormally proliferating synovial fibroblasts (FLS cells). The aim of this review is to comprehensively summarize the therapeutic potential of TCM for RA using ferroptosis as a therapeutic pathway. The aim is to provide a scientific basis for the clinical application of TCM in RA. In major scientific databases (including PubMed, Web of Science, ScienceDirect, and CNKI, covering literature published up to June 2025). The search strategy combines “Chinese medicine”, “TCM”, “ferroptosis”, and “rheumatoid arthritis”, using Boolean operators (AND, OR). This review systematically elucidates the mechanistic underpinnings through which TCM mitigates RA by modulating ferroptosis pathways. This review highlights the potential that Chinese medicine holds in the treatment of RA. The use of ferroptosis as a therapeutic pivot provides new ideas for the treatment of RA and promotes the integration of Western and Chinese medicine.
- 19 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1768013
Open AccessFerroptosis as a therapeutic nexus: traditional Chinese medicine interventions in rheumatoid arthritis
Ferroptosis is an iron-dependent, lipid peroxidation-driven form of programmed cell death that plays an important role in neurodegenerative, neoplastic, and autoimmune diseases. Recent studies in Rheumatoid arthritis (RA) have shown that iron metabolism disorders caused by iron overload and impaired transferrin function lead to the production of reactive oxygen species; ferroptosis-associated pathways, such as dysregulation of the System Xc - /GPX4 axis dysregulation, NCOA4-mediated ferritin autophagy, endoplasmic reticulum stress and ferroptosis pathway crosstalk; as well as ferroptosis plays a regulatory role in a variety of immune cells, such as T-cells, B-cells, macrophages, etc., which collectively constitute a complex disease regulatory network in RA. Studies have shown that traditional Chinese medicine (TCM) and TCM therapeutics can alleviate RA-related symptoms and improve the disease progression and prognosis of RA by regulating iron metabolism, activating the Nrf2/HO-1 antioxidant pathway, and removing abnormally proliferating synovial fibroblasts (FLS cells). The aim of this review is to comprehensively summarize the therapeutic potential of TCM for RA using ferroptosis as a therapeutic pathway. The aim is to provide a scientific basis for the clinical application of TCM in RA. In major scientific databases (including PubMed, Web of Science, ScienceDirect, and CNKI, covering literature published up to June 2025). The search strategy combines “Chinese medicine”, “TCM”, “ferroptosis”, and “rheumatoid arthritis”, using Boolean operators (AND, OR). This review systematically elucidates the mechanistic underpinnings through which TCM mitigates RA by modulating ferroptosis pathways. This review highlights the potential that Chinese medicine holds in the treatment of RA. The use of ferroptosis as a therapeutic pivot provides new ideas for the treatment of RA and promotes the integration of Western and Chinese medicine.
- Open Access
- 1 January 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 2 (4) , 202625
Targeting FSP1 to induce ferroptosis in cancer: From mechanisms to therapeutic strategies
Ferroptosis is a form of programmed cell death driven by iron-dependent lipid peroxidation. Inducing ferroptosis in tumor cells has emerged as a crucial strategy for cancer treatment and overcoming therapeutic resistance. Ferroptosis suppressor protein 1 (FSP1), identified in recent years, is a key ferroptosis-inhibitory factor that operates independently of glutathione peroxidase 4 (GPX4). FSP1 is highly expressed in multiple malignant tumors, and its expression levels are tightly associated with unfavorable patient prognosis, treatment resistance, and tumor progression. Specific stresses within the tumor microenvironment, including hypoxia, metabolic stress, and the development of drug resistance, can drive a shift in ferroptosis resistance mechanisms from GPX4-dependent to FSP1-dependent pathways. Such plasticity renders FSP1 a druggable target in specific cancer genotypes or at particular stages of tumor progression. Indeed, genetic or pharmacological inhibition of FSP1 has yielded potent antitumor effects across diverse preclinical models. This review systematically summarizes the structural characteristics of FSP1, the molecular mechanisms through which it suppresses ferroptosis, the multilayered regulatory networks controlling its activity, and its roles in different malignancies. We deeply analyze the plasticity of FSP1 dependency in tumor cells in vivo and comprehensively review the latest preclinical progress on small-molecule FSP1 inhibitors and related combinatorial therapeutic strategies. This review aims to establish a theoretical framework to support the clinical translation of FSP1-targeted antitumor strategies.
- 1 January 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 2 (4) , 202625
Open AccessTargeting FSP1 to induce ferroptosis in cancer: From mechanisms to therapeutic strategies
Ferroptosis is a form of programmed cell death driven by iron-dependent lipid peroxidation. Inducing ferroptosis in tumor cells has emerged as a crucial strategy for cancer treatment and overcoming therapeutic resistance. Ferroptosis suppressor protein 1 (FSP1), identified in recent years, is a key ferroptosis-inhibitory factor that operates independently of glutathione peroxidase 4 (GPX4). FSP1 is highly expressed in multiple malignant tumors, and its expression levels are tightly associated with unfavorable patient prognosis, treatment resistance, and tumor progression. Specific stresses within the tumor microenvironment, including hypoxia, metabolic stress, and the development of drug resistance, can drive a shift in ferroptosis resistance mechanisms from GPX4-dependent to FSP1-dependent pathways. Such plasticity renders FSP1 a druggable target in specific cancer genotypes or at particular stages of tumor progression. Indeed, genetic or pharmacological inhibition of FSP1 has yielded potent antitumor effects across diverse preclinical models. This review systematically summarizes the structural characteristics of FSP1, the molecular mechanisms through which it suppresses ferroptosis, the multilayered regulatory networks controlling its activity, and its roles in different malignancies. We deeply analyze the plasticity of FSP1 dependency in tumor cells in vivo and comprehensively review the latest preclinical progress on small-molecule FSP1 inhibitors and related combinatorial therapeutic strategies. This review aims to establish a theoretical framework to support the clinical translation of FSP1-targeted antitumor strategies.
- Open Access
- 1 January 2026
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 32 (1) , e75-e78
Correspondence to editorial on “CD36 Promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma”
Correspondence to editorial “Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma”
- 1 January 2026
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 32 (1) , e75-e78
Open AccessCorrespondence to editorial on “CD36 Promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma”
Correspondence to editorial “Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma”
- Open Access
- 8 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Metabolic support protects mucosa from ferroptosis in radiation-induced mucositis
Ionizing radiation is effective in treating cancer but causes significant damage to the mucosa, thereby increasing patient discomfort, delaying therapy, and raising the risk of mortality. The underlying mechanisms of this damage remain poorly understood, and current treatments are largely palliative. In this study, ferroptosis was identified as the primary mode of cell death responsible for the radiation-induced depletion of oral mucosal epithelial cells. Notably, a compensatory phase was also discovered in the early stages following radiation exposure, during which fibroblasts provide crucial metabolic support. Specifically, fibroblasts supply polyamines that are readily absorbed by basal epithelial cells, protecting them from ferroptosis. Supplementation with polyamines was found to effectively prevent mucosal injury. These findings highlight the critical role of fibroblast-mediated metabolic support in protecting the oral mucosa from radiation-induced damage and offer insights into enhancing the body’s intrinsic protective mechanisms against radiation-related diseases.
- 8 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMetabolic support protects mucosa from ferroptosis in radiation-induced mucositis
Ionizing radiation is effective in treating cancer but causes significant damage to the mucosa, thereby increasing patient discomfort, delaying therapy, and raising the risk of mortality. The underlying mechanisms of this damage remain poorly understood, and current treatments are largely palliative. In this study, ferroptosis was identified as the primary mode of cell death responsible for the radiation-induced depletion of oral mucosal epithelial cells. Notably, a compensatory phase was also discovered in the early stages following radiation exposure, during which fibroblasts provide crucial metabolic support. Specifically, fibroblasts supply polyamines that are readily absorbed by basal epithelial cells, protecting them from ferroptosis. Supplementation with polyamines was found to effectively prevent mucosal injury. These findings highlight the critical role of fibroblast-mediated metabolic support in protecting the oral mucosa from radiation-induced damage and offer insights into enhancing the body’s intrinsic protective mechanisms against radiation-related diseases.
- Open Access
- 1 July 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (3) , 960-980
CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma
CD36 Promotes Iron Accumulation and Dysfunction in CD8+ T Cells via the p38-CEBPB-TfR1 Axis in Early-stage Hepatocellular Carcinoma
- 1 July 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (3) , 960-980
Open AccessCD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma
CD36 Promotes Iron Accumulation and Dysfunction in CD8+ T Cells via the p38-CEBPB-TfR1 Axis in Early-stage Hepatocellular Carcinoma
- Open Access
- 11 February 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1531874
Dicoumarol sensitizes hepatocellular carcinoma cells to ferroptosis induced by imidazole ketone erastin
Introduction: Ferroptosis, an iron-dependent form of regulated cell death, is characterized by the lethal accumulation of lipid peroxides on cellular membranes. It not only inhibits tumor growth but also enhances immunotherapy responses and overcomes drug resistance in cancer therapy. The inhibition of the cystine-glutamate antiporter, system Xc–, induces ferroptosis. Imidazole ketone erastin (IKE), an inhibitor of the system Xc– functional subunit solute carrier family 7 member 11 (SLC7A11), is an effective and metabolically stable inducer of ferroptosis with potential in vivo applications. However, tumor cells exhibited differential sensitivity to IKE-induced ferroptosis. The intrinsic factors determining sensitivity to IKE-induced ferroptosis remain to be explored to improve its efficacy.Methods: Bulk RNA-sequencing data from hepatocellular carcinoma (HCC) and normal liver tissues were collected from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. Differentially expressed genes were identified and intersected with the ferroptosis-related genes (FRGs) listed in the FerrDb database, yielding the identification of 13 distinct FRGs.Results: A ferroptosis signature index model (Risk Score) was developed to predict HCC prognosis. And SLC7A11 and NAD(P)H quinone dehydrogenase 1 (NQO1) were identified as candidate FRGs indicating poor prognosis of HCC. Dicoumarol (DIC), an inhibitor of NQO1, was subsequently employed to assess its sensitizing effects on IKE in HCC treatment. In HCC cell lines and the subcutaneous xenograft model, the combined suppression of SLC7A11 and NQO1 significantly enhanced the inhibitory effect on tumor growth by inducing ferroptosis.Discussion: In conclusion, our findings demonstrate that DIC sensitized HCC cells to IKE-induced ferroptosis in HCC. Moreover, the identification of potential drugs that enhance the susceptibility of HCC cells to ferroptosis could provide novel therapeutic strategies for the treatment of HCC.
- 11 February 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1531874
Open AccessDicoumarol sensitizes hepatocellular carcinoma cells to ferroptosis induced by imidazole ketone erastin
Introduction: Ferroptosis, an iron-dependent form of regulated cell death, is characterized by the lethal accumulation of lipid peroxides on cellular membranes. It not only inhibits tumor growth but also enhances immunotherapy responses and overcomes drug resistance in cancer therapy. The inhibition of the cystine-glutamate antiporter, system Xc–, induces ferroptosis. Imidazole ketone erastin (IKE), an inhibitor of the system Xc– functional subunit solute carrier family 7 member 11 (SLC7A11), is an effective and metabolically stable inducer of ferroptosis with potential in vivo applications. However, tumor cells exhibited differential sensitivity to IKE-induced ferroptosis. The intrinsic factors determining sensitivity to IKE-induced ferroptosis remain to be explored to improve its efficacy.Methods: Bulk RNA-sequencing data from hepatocellular carcinoma (HCC) and normal liver tissues were collected from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. Differentially expressed genes were identified and intersected with the ferroptosis-related genes (FRGs) listed in the FerrDb database, yielding the identification of 13 distinct FRGs.Results: A ferroptosis signature index model (Risk Score) was developed to predict HCC prognosis. And SLC7A11 and NAD(P)H quinone dehydrogenase 1 (NQO1) were identified as candidate FRGs indicating poor prognosis of HCC. Dicoumarol (DIC), an inhibitor of NQO1, was subsequently employed to assess its sensitizing effects on IKE in HCC treatment. In HCC cell lines and the subcutaneous xenograft model, the combined suppression of SLC7A11 and NQO1 significantly enhanced the inhibitory effect on tumor growth by inducing ferroptosis.Discussion: In conclusion, our findings demonstrate that DIC sensitized HCC cells to IKE-induced ferroptosis in HCC. Moreover, the identification of potential drugs that enhance the susceptibility of HCC cells to ferroptosis could provide novel therapeutic strategies for the treatment of HCC.
- Top Cited PapersOpen Access
- 24 June 2024
- Published by Elsevier in Redox Biology
- Vol. 75, 103255
Inhibition of ferroptosis rescues M2 macrophages and alleviates arthritis by suppressing the HMGB1/TLR4/STAT3 axis in M1 macrophages
- 24 June 2024
- Published by Elsevier in Redox Biology
- Vol. 75, 103255
Top Cited PapersOpen AccessInhibition of ferroptosis rescues M2 macrophages and alleviates arthritis by suppressing the HMGB1/TLR4/STAT3 axis in M1 macrophages
- Top Cited PapersOpen Access
- 18 October 2022
- Published by Elsevier in Redox Biology
- Vol. 57, 102509
Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model
- 18 October 2022
- Published by Elsevier in Redox Biology
- Vol. 57, 102509
Top Cited PapersOpen AccessInhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model
- Open Access
- 23 May 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 911564
Roles of Ferroptosis in Cardiovascular Diseases
Ferroptosis is an iron-dependent regulated cell death characterized by lipid peroxidation and iron overload, which is different from other types of programmed cell death, including apoptosis, necroptosis, autophagy, and pyroptosis. Over the past years, emerging studies have shown a close relation between ferroptosis and various cardiovascular diseases such as atherosclerosis, acute myocardial infarction, ischemia/reperfusion injury, cardiomyopathy, and heart failure. Herein, we will review the contributions of ferroptosis to multiple cardiovascular diseases and the related targets. Further, we discuss the potential ferroptosis-targeting strategies for treating different cardiovascular diseases.
- 23 May 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 911564
Open AccessRoles of Ferroptosis in Cardiovascular Diseases
Ferroptosis is an iron-dependent regulated cell death characterized by lipid peroxidation and iron overload, which is different from other types of programmed cell death, including apoptosis, necroptosis, autophagy, and pyroptosis. Over the past years, emerging studies have shown a close relation between ferroptosis and various cardiovascular diseases such as atherosclerosis, acute myocardial infarction, ischemia/reperfusion injury, cardiomyopathy, and heart failure. Herein, we will review the contributions of ferroptosis to multiple cardiovascular diseases and the related targets. Further, we discuss the potential ferroptosis-targeting strategies for treating different cardiovascular diseases.